Safety of High-Intensity Statins in the Veteran Population: Atorvastatin 40 to 80 mg Compared With Rosuvastatin 20 to 40 mg.  Stein B, Ward T, Hale G, Lyver E.  Ann Pharmacother. 2019 Nov 12:1060028019888487. doi: 10.1177/1060028019888487.

Atorvastatin Exerts Antileukemia Activity via Inhibiting Mevalonate-YAP Axis in K562 and HL60 Cells.  Zhang L, Chen T, Dou Y, Zhang S, Liu H, Khishignyam T, Li X, Zuo D, Zhang Z, Jin M, Wang R, Qiu Y, Zhong Y, Kong D.  Front Oncol. 2019 Oct 9;9:1032. doi: 10.3389/fonc.2019.01032.

Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients.  Lee N, Maeda K, Fukizawa S, Ieiri I, Tomaru A, Akao H, Takeda K, Iwadare M, Niwa O, Masauji T, Yamane N, Kajinami K, Kusuhara H, Sugiyama Y.  Drug Metab Pharmacokinet. 2019 Aug 29. pii: S1347-4367(19)30068-0. doi: 10.1016/j.dmpk.2019.08.004.

Phase I/IIa Trial of Atorvastatin in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysm.  Tremoulet AH, Jain S, Jone PN, Best BM, Duxbury EH, Franco A, Printz B, Dominguez SR, Heizer H, Anderson MS, Glodé MP, He F, Padilla RL, Shimizu C, Bainto E, Pancheri J, Cohen HJ, Whitin JC, Burns JC.  J Pediatr. 2019 Sep 24. pii: S0022-3476(19)30972-2. doi: 10.1016/j.jpeds.2019.07.064.

Impaired Glucagon Suppression And Reduced Insulin Sensitivity In Subjects With Prediabetes Undergoing Atorvastatin Therapy.  Urbano F, Di Pino A, Scicali R, Filippello A, Di Mauro S, Scamporrino A, Marchisello S, Rabuazzo AM, Purrello F, Piro S.  Eur J Endocrinol. 2019 Sep 1. pii: EJE-19-0173.R2. doi: 10.1530/EJE-19-0173.

A novel direct method to determine adherence to atorvastatin therapy in patients with coronary heart disease.  Kristiansen O, Vethe NT, Fagerland MW, Bergan S, Munkhaugen J, Husebye E.  Br J Clin Pharmacol. 2019 Sep 8. doi: 10.1111/bcp.14122.

Treatment with Free Triple Combination Therapy of Atorvastatin, Perindopril, Amlodipine in Hypertensive Patients: A Real-World Population Study in Italy.  Perrone V, Veronesi C, Gambera M, Nati G, Perone F, Tagliabue PF, Degli Esposti L, Volpe M.  High Blood Press Cardiovasc Prev. 2019 Oct;26(5):399-404. doi: 10.1007/s40292-019-00336-2.

Impact of Macroprolactinemia on Cardiometabolic Effects of Atorvastatin in Women With Hypercholesterolemia.  Krysiak R, Kowalcze K, Okopień B.  Am J Cardiol. 2019 Oct 15;124(8):1207-1212. doi: 10.1016/j.amjcard.2019.07.017

Effects of Preoperative Atorvastatin Treatment On Erectile Function After Radical Prostatectomy: Results From a Subgroup of ESTO1, a Randomized, Double-Blind, Placebo-Controlled Study.  Siltari A, Riikonen J, Fode M, Murtola TJ.  J Sex Med. 2019 Oct;16(10):1597-1605. doi: 10.1016/j.jsxm.2019.07.001

Atorvastatin attenuates cardiac hypertrophy through AMPK/miR-143-3p/Bcl2 axis.  Sun J, Zhang C, Zhang Z.  Arch Physiol Biochem. 2019 Jul 29:1-7. doi: 10.1080/13813455.2019.1643377.

Atorvastatin Attenuates Cold-Induced Hypertension by Preventing Gut Barrier Injury.  Zhang S, Zhang Y, Ahsan MZ, Yuan Y, Liu G, Han X, Zhang J, Zhao X, Bai B, Li Y.  J Cardiovasc Pharmacol. 2019 Aug;74(2):143-151. doi: 10.1097/FJC.0000000000000690.

The Effect of Atorvastatin (and Subsequent Metformin) on Adipose Tissue Acylation-Stimulatory-Protein Concentration and Inflammatory Biomarkers in Overweight/Obese Women With Polycystic Ovary Syndrome.  Sathyapalan T, Hobkirk JP, Javed Z, Carroll S, Coady AM, Pemberton P, Smith A, Cianflone K, Atkin SL.  Front Endocrinol (Lausanne). 2019 Jun 25;10:394. doi: 10.3389/fendo.2019.00394

Comparison of efficacy and safety of atorvastatin 5% lotion and betamethasone 0.1% lotion in the treatment of scalp seborrheic dermatitis.  Sobhan M, Gholampoor G, Firozian F, Mohammadi Y, Mehrpooya M.  Clin Cosmet Investig Dermatol. 2019 Apr 29;12:267-275. doi: 10.2147/CCID.S196412.

Treatment of Relapsed Chronic Subdural Hematoma in Four Young Children with Atorvastatin and Low-dose Dexamethasone.  Huang J, Li L, Zhang J, Gao C, Quan W, Tian Y, Sun J, Tian Q, Wang D, Dong J, Zhang J, Jiang R.  Pharmacotherapy. 2019 Jul;39(7):783-789. doi: 10.1002/phar.2276.

Efficacy and Safety of Ezetimibe in Combination with Atorvastatin for Acute Coronary Syndrome Patients Accompanied with Type 2 Diabetes: A Single-Center, Non-randomized Cohort Study.  Huang Z, Li Q, Ye W, Zhang Q, Li X.  Chem Pharm Bull (Tokyo). 2019;67(5):419-425. doi: 10.1248/cpb.c18-00685.

Atorvastatin Has a Dose-Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double-Blind Randomized Controlled Trials.  Vogt L, Bangalore S, Fayyad R, Melamed S, Hovingh GK, DeMicco DA, Waters DD.  J Am Heart Assoc. 2019 May 7;8(9):e010827. doi: 10.1161/JAHA.118.010827.

A Multicenter, Randomized, Placebo-Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis.  Kitas GD, Nightingale P, Armitage J, Sattar N, Belch JJF, Symmons DPM; TRACE RA Consortium.  Arthritis Rheumatol. 2019 Sep;71(9):1437-1449. doi: 10.1002/art.40892.

Comparison of Rosuvastatin Versus Atorvastatin for Coronary Plaque Stabilization.  Thondapu V, Kurihara O, Yonetsu T, Russo M, Kim HO, Lee H, Soeda T, Minami Y, Jang IK.  Am J Cardiol. 2019 May 15;123(10):1565-1571. doi: 10.1016/j.amjcard.2019.02.019.

Atorvastatin Prevents Myocardial Fibrosis in Spontaneous Hypertension via Interleukin-6 (IL-6)/Signal Transducer and Activator of Transcription 3 (STAT3)/Endothelin-1 (ET-1) Pathway.  Fang T, Guo B, Xue L, Wang L.  Med Sci Monit. 2019 Jan 11;25:318-323. doi: 10.12659/MSM.912032.

Safety

Acute Colchicine-induced Neuromyopathy in a Patient Treated with Atorvastatin and Clarithromycin.  Olmos-Martínez JM, Molina H, Salas C, Olmos JM, Hernández JL.  Eur J Case Rep Intern Med. 2019 Mar 18;6(3):001066. doi: 10.12890/2019_001066

Acute renal failure secondary to rhabdomyolysis in a patient receiving treatment with ticagrelor and atorvastatin.  Martín Navarro JA, Gutiérrez Sánchez MJ, Petkov Stoyanov V, Jiménez Herrero MC.  Nefrologia. 2019 Jul - Aug;39(4):448-450. doi: 10.1016/j.nefro.2018.10.012.

Atorvastatin, a member of the statin family and one of the statin class inhibitors, is a lipidic agent that lowers levels of 3-hydroxy-3-methylgutaryl-CoA (HMG-CoA) reductase, so as to reduce elevated level of low density lipoproteins (LDL) cholesterol and cardiovascular risk.

In addition to its anti-cholesterol properties, atorvastatin has been shown to suppress the proliferation of cancer cells and induce apoptosis (1) and also playing a role in immunosuppression, fighting inflammation (there is a close association between inflammation and tumor), preventing dementia.

However, it has a problem of scarce gastric solubility and low total bioavailability together with higher pre-system clearance.

It has also demonstrated an antifungal ability against Candida albicans in vivo and in vitro (2).

in this study atorvastatin demonstrated positive effects on erectile function after radical prostatectomy surgery (3).

It also limited the influenza virus to generate lipid droplets and greatly suppresses virus replication (4).

Like all drugs it can cause side effects. Always consult your doctor.

Atorvastatin studies

Molecular Formula:  C₃₃H₃₅FN₂O₅

Molecular Weight: 1209.4 g/mol

CAS:  134523-00-5   110862-48-1

UNII: A0JWA85V8F

Sinonimi:

• Cardyl
• Tozalip
• Liprimar
• atrovastin
• Lipotropic
• Vastina
• Xanator
• Zurinel
• Atogal
• Atorin
• Lowden
• Sincol
• Ator
• Atofast
• Atorcor
• Atorlip
• Atorpic
• Faboxim
• Lipilou
• Lipinon
• Torvacard
• Tulip
• Xavator
• Xarator
• Sotis
• Lipitor
• Torvast
• (R-(R*,R*))-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
• (betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid
• (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid
• 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, (R-(R*,R*))-
• (3R,5R)-7-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid
• (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid
• (3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid
• 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, (betaR,deltaR)-

References___________________________________________________

(1) Proteome and phosphoproteome reveal mechanisms of action of atorvastatin against esophageal squamous cell carcinoma.  Yuan Q, Dong CD, Ge Y, Chen X, Li Z, Li X, Lu Q, Peng F, Wu X, Zhao J, Liu K.  Aging (Albany NY). 2019 Nov 7;11. doi: 10.18632/aging.102402.

(2) Assessment of the in vitro and in vivo activity of atorvastatin against Candida albicans.  Ajdidi A, Sheehan G, Abu Elteen K, Kavanagh K.  J Med Microbiol. 2019 Oct;68(10):1497-1506. doi: 10.1099/jmm.0.001065.

(3) Effects of Preoperative Atorvastatin Treatment On Erectile Function After Radical Prostatectomy: Results From a Subgroup of ESTO1, a Randomized, Double-Blind, Placebo-Controlled Study.  Siltari A, Riikonen J, Fode M, Murtola TJ.  J Sex Med. 2019 Oct;16(10):1597-1605. doi: 10.1016/j.jsxm.2019.07.001

(4) Atorvastatin restricts the ability of influenza virus to generate lipid droplets and severely suppresses the replication of the virus.  Episcopio D, Aminov S, Benjamin S, Germain G, Datan E, Landazuri J, Lockshin RA, Zakeri Z.  FASEB J. 2019 Aug;33(8):9516-9525. doi: 10.1096/fj.201900428RR.